# Request for a License To Export Deuterium
Pursuant to 10 CFR 110.70 (b) “Public Notice of Receipt of an Application,” please take notice that the U.S. Nuclear Regulatory Commission (NRC) has received the following request for an export license. Copies of the request are available electronically through ADAMS and can be accessed through the Public Electronic Reading Room (PERR) link *http://www.nrc.gov/reading-rm.html* at the NRC Homepage.
A request for a hearing or petition for leave to intervene may be filed within thirty days after publication of this notice in the *Federal Register* . Any request for hearing or petition for leave to intervene shall be served by the requestor or petitioner upon the applicant, the Office of the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555; the Office of Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555; and the Executive Secretary, U.S. Department of State, Washington, DC 20520.
A request for a hearing or petition for leave to intervene may be filed with the NRC electronically in accordance with NRC's E-Filing rule promulgated in August 2007, 72 FR 49139 (Aug. 28, 2007). Information about filing electronically is available on the NRC's public Web site at *http://www.nrc.gov/site-help/e-submittals.html* . To ensure timely electronic filing, at least 5 (five) days prior to the filing deadline, the petitioner/requestor should contact the Office of the Secretary by email at *[email protected]* , or by calling (301) 415-1677, to request a digital ID certificate and allow for the creation of an electronic docket.
In addition to a request for hearing or petition for leave to intervene, written comments, in accordance with 10 CFR 110.81, should be submitted within thirty (30) days after publication of this notice in the *Federal Register* to Office of the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555, Attention: Rulemaking and Adjudications.
The information concerning this export license application follows.
| Name of applicant, | Material type | Total quantity | End use | Recipient country |
| --- | --- | --- | --- | --- |
| Concert Pharmaceuticals, Inc. | Heavy water (D
O) | ~20,000.0 kgs | Non-nuclear end-use in active pharmaceutical ingredient manufacturing. | Portugal, Austria |
For the Nuclear Regulatory Commission.
Dated this 20th day of December 2013 in Rockville, Maryland.
Stephen Dembek,
Acting Deputy Director, Office of International Programs.